BUSINESS
Kyowa Kirin Looks to Derive 40% of Sales Overseas by 2020, Split from Holdings Firm Won’t Happen: Pres.
Kyowa Hakko Kirin aims to generate 40% of its pharmaceutical revenues (excluding those of Kyowa Hakko Bio) outside Japan through independent sales and marketing in FY2020, the last year of its next five-year business plan, President Nobuo Hanai said. As…
To read the full story
Related Article
- Drug Pricing Tomorrow: Full Interview with MHLW Councilor Takeda - Part 2
September 10, 2015
BUSINESS
- Teikoku to Market Medipost’s Knee OA Cell Therapy in Japan
December 22, 2025
- Clinigen Japan Adds 4 Products, Including Takeda’s Buccolam
December 22, 2025
- Meiji Backs US Incubator MBC BioLabs to Boost Open Innovation
December 22, 2025
- Boehringer Passes on Option for Nxera’s Schizophrenia Program
December 22, 2025
- Otsuka Kicks Off Global PIII of Phenylketonuria Drug
December 22, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…





